Full Text of PDF (422k)
Article in Japanese
Abstract
Case Report
A case of drug-induced pneumonia caused by dasatinib
Yasuhiro Kimuraa Yoshitaka Teia Reiko Sadoa Naoki Miyazawaa Takeshi Kanekob
aDepartment of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital
bDepartment of Pulmonology, Yokohama City University Graduate School of Medicine
ABSTRACT
A 49-year-old male with chronic myelogenous leukemia (CML) complained of dyspnea on effort and dry cough after 2 months of administration of dasatinib. Chest computed tomography (CT) showed consolidation in the right middle and lower lobes and bilateral ground glass opacity in the lower lobes. Since neither infectious disease nor collagen disease was indicated on bronchoscopy, we diagnosed drug-induced pneumonia due to dasatinib. Treatment with prednisolone starting at 30 mg/day improved the symptoms and the shadow on the chest CT. Imatinib was administered against the relapse of CML, but no relapse of pneumonia was observed. Dasatinib and imatinib are both classified as tyrosine kinase inhibitors that target BCR-ABL1, but this case suggests that imatinib may be safely administered to patients who have had previous lung injury as a result of dasatinib.
KEYWORDS
Drug-induced lung disease Dasatinib Interstitial pneumonia Imatinib
Received 3 May 2020 ／ Accepted 17 Feb 2021
AJRS, 10(3): 277-282, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.